New mechanism that shields persister tumor cells from immune system identified

Cancer therapies do not always succeed in eliminating tumor cells. Some of these cells enter a state of senescence—a latent, non-dividing state that is generally irreversible. Others, however, enter a state known as “persistence,” where dormancy is temporary and reversible. This state allows the cells to begin growing again after the treatment has ended, leading to cancer recurrence.

Exploring novel deep learning-based models for cancer histopathology image analysis

Histopathological evaluation of tumor specimens has long been essential in diagnosing breast cancer and guiding clinical decision-making. However, one of the key challenges in routine diagnostics includes the inter-observer and inter-lab variabilities present in the assessment of prognostic markers that could lead to under- and over-treatment of patients.

Phase III trial finds trastuzumab emtansine improves long-term survival in HER2 breast cancer

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the Phase III KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center.